Last updated: October 7, 2026
ArriVent’s firmonertinib missed FURVENT’s primary endpoint in first line EGFR exon 20 insertion lung cancer (hazard ratio 0.75, p=0.0654), sending AVBP down 47.0%, while Vaxcyte priced roughly $1 billion in stock and convertible notes and Stryker set Spencer Stiles to succeed Kevin Lobo as CEO on January 1, 2027.
This page covers the business day of Tuesday, October 6, 2026, with settled closing prices from that session.
Why did ArriVent’s firmonertinib fail its Phase 3 FURVENT trial?
FURVENT missed its primary endpoint of progression free survival by blinded independent central review: the 240 mg dose produced a hazard ratio of 0.75 against chemotherapy with p=0.0654, short of statistical significance, even though response rates and investigator assessed PFS favored the drug.
ArriVent BioPharma announced the topline result on October 6, 2026, in a release filed as exhibit 99.1 to an 8-K. FURVENT (NCT05607550) was a global, three arm pivotal Phase 3 that enrolled 398 patients with previously untreated, locally advanced or metastatic non squamous non small cell lung cancer carrying EGFR exon 20 insertion mutations, across sites in the United States, Europe, Japan, and China. Patients were randomized to firmonertinib at 240 mg or 160 mg once daily, or to platinum based chemotherapy with pemetrexed, the control regimen.
The 240 mg arm delivered a median PFS of 11.0 months by central review against 9.5 months for chemotherapy. That 1.5 month difference, with a hazard ratio of 0.75 and a 95% confidence interval of 0.55 to 1.02, landed at p=0.0654, above the threshold needed to declare the trial positive. The 160 mg arm delivered 8.4 months, a 0.91 hazard ratio, indistinguishable from control. CEO Bing Yao called the results disappointing and said the company is evaluating the full dataset to determine the most appropriate development path for firmonertinib, which holds FDA Breakthrough Therapy designation in this population.
What exactly did FURVENT show at each dose?
The two firmonertinib doses behaved like different drugs: 240 mg nearly doubled the confirmed response rate of chemotherapy and added four months of investigator assessed PFS, while 160 mg matched chemotherapy on response and ran behind it on central review PFS.
| Measure | Firmonertinib 240 mg | Firmonertinib 160 mg | Chemotherapy |
|---|---|---|---|
| Median PFS, blinded central review | 11.0 months | 8.4 months | 9.5 months |
| Hazard ratio vs control (95% CI) | 0.75 (0.55 to 1.02), p=0.0654 | 0.91 (0.67 to 1.25) | Reference |
| Median PFS, investigator assessed | 11.1 months | 8.3 months | 7.1 months |
| Confirmed objective response rate | 60% | 35% | 33% |
| Grade 3 or higher treatment related adverse events | 26% | 22% | 40% |
All figures are from ArriVent’s October 6 release. The company reported no new safety signals. The divergence between the central review and investigator reads at 240 mg (a 9.5 month control median by central review against 7.1 by investigator assessment) will be one of the first things analysts ask about when the full dataset is presented.
What does the FURVENT failure mean for the exon 20 field?
First line treatment of EGFR exon 20 insertion lung cancer stays with amivantamab plus chemotherapy, and the nearest branded challenger is now Cullinan’s zipalertinib, which faces a second line FDA decision on February 27, 2027, with a first line rolling submission in progress.
EGFR exon 20 insertion mutations have historically resisted the EGFR inhibitors that transformed treatment of more common EGFR mutations, which is why the niche has its own development race. Johnson & Johnson’s amivantamab, in combination with chemotherapy, is the approved first line standard in this mutation. Firmonertinib at 240 mg was the most advanced oral challenger to that position; FURVENT’s miss removes it from the near term first line picture.
The readacross runs in two directions for Cullinan Therapeutics. A rival’s exit reduces future competitive pressure on zipalertinib, but FURVENT is also a reminder that this mutation punishes progression free survival trials, with a control arm that performed better by central review than many expected. CGEM closed at 16.25 on October 6, up 1.3% on the session, a quiet print on a day its nearest competitor lost nearly half its value. ArriVent closed at 15.09, down 47.0% from Monday’s 28.46 (our arithmetic from settled closes).
What did Vaxcyte’s $1 billion offering include?
Vaxcyte priced two concurrent offerings late on October 6: roughly $500 million of equity at $64.00 per share and $500 million of 1.50% convertible senior notes due 2032 with an initial conversion price near $89.60, about 40% above the stock price. Both close October 9.
| Term | Equity offering | Convertible notes |
|---|---|---|
| Size | About $500 million gross | $500 million principal |
| Structure | 7,412,500 shares at $64.00, plus 400,000 pre funded warrants at $63.999 | 1.50% coupon, paid semi annually, maturing October 15, 2032 |
| Conversion | Not applicable | 11.1607 shares per $1,000 principal, an initial conversion price of about $89.60, roughly 40% above the offering price |
| Additional purchase options | Up to 1,171,875 additional shares, 30 days | Up to $75 million additional principal |
| Expected close | October 9, 2026 | October 9, 2026 |
Terms are from Vaxcyte’s pricing release of October 6 and its preliminary prospectus supplement filed October 5. The company says proceeds will fund clinical development of its VAX-31 programs, manufacturing scale up, commercial preparation for a US launch, and research on other candidates.
Why did Vaxcyte raise capital the day after its OPUS-1 rally?
Because the window was open: OPUS-1’s positive readout on Monday repriced PCVX up 30.7%, and the company converted that mark into roughly $1 billion of funding before the next data event, paying a 1.50% coupon on half of it.
The sequence was fast. Vaxcyte’s VAX-31 pneumococcal vaccine met all primary endpoints in its pivotal adult Phase 3 on Monday morning, October 5, and PCVX closed that day at 73.82, up 30.7% from its pre data close. On Tuesday morning the company announced the proposed offerings; PCVX closed the session at 66.70, down 9.6%, and the equity priced after the close at $64.00, about 4.0% below that settled close (our arithmetic). The structure is notable: by raising half the total as convertible debt with conversion struck roughly 40% above the stock, Vaxcyte limited immediate dilution and effectively borrowed against the credibility OPUS-1 created. The next readouts on the calendar, OPUS-2 and OPUS-3, land in the first half of 2027, with a BLA planned for the first half of 2028.
The capital markets context cuts both ways. Spyre Therapeutics, which priced a $350.0 million offering at $85.00 per share on Monday evening, saw its first session after pricing close at 80.11 on Tuesday, down 13.6% from Monday and about 5.8% below the offer price (our arithmetic). The follow on window is open, but the market is setting the clearing price, not the issuers.
What did epcoritamab show in first line DLBCL in EPCORE DLBCL-2?
Epcoritamab plus R-CHOP cut the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B cell lymphoma, with a hazard ratio of 0.49 (p<0.0001) in the primary IPI 3 to 5 population and an identical 0.49 across all enrolled patients.
| Population | Hazard ratio for PFS (95% CI) | p value |
|---|---|---|
| IPI 3 to 5 (primary endpoint) | 0.49 (0.35 to 0.69) | p<0.0001 |
| All patients, IPI 2 to 5 (key secondary) | 0.49 (0.36 to 0.67) | p<0.0001 |
AbbVie and Genmab announced the topline result on Monday, October 5. EPCORE DLBCL-2 (NCT05578976) randomized newly diagnosed patients 2:1 to epcoritamab plus R-CHOP for six cycles followed by two cycles of epcoritamab alone, or to R-CHOP for six cycles followed by two cycles of rituximab. The release did not disclose median PFS values or patient counts, which are being held for a medical meeting, and the companies said they will engage global regulatory authorities on next steps. The safety profile was described as consistent with the known profiles of the individual agents.
The commercial frame: a first line label would put a CD3xCD20 bispecific inside the DLBCL induction backbone, territory where Roche’s Polivy combination has been building share since its own first line approval. Epcoritamab is already approved in relapsed settings, and its earlier first line monotherapy focused trial, EPCORE DLBCL-1, missed on overall survival earlier this year, making the combination result the program’s route into front line use. For Genmab, it capped a two readout week: the Rina-S ovarian cancer data landed Saturday, and both readouts were in Monday’s tape when GMAB rose 10.7%, a move our Tuesday edition attributed to Rina-S alone. GMAB closed Tuesday at 37.80, down 1.8%.
What did BD agree to with the US government?
BD pledged $19 billion in US capital, operational, and supply chain investment over several years, including $3 billion for manufacturing expansion, in exchange for relief from future Section 232 tariffs on applicable products, per the company’s statement as reported by Reuters and Fierce Pharma.
The announcement, made October 6, makes BD the first large medical device maker to strike the kind of investment for tariff relief arrangement that several large pharmaceutical companies have signed this year. Per the company’s stated goals, the program would add annual US production capacity for 5 billion essential medical consumables such as syringes and catheters, bring about 80% of the consumables BD supplies to the US market onto domestic production, and use American made steel in 100% of BD products made for US use. BD operates US plants in Nebraska, Connecticut, Texas, Georgia, Utah, South Carolina, and Puerto Rico.
Two caveats belong in any reading of the deal. First, BD itself notes that the final tariff rates, timing, and product scope it is gaining relief from are not yet set, so the financial value of the relief cannot be quantified. Second, we did not retrieve a primary release document on Tuesday night; the figures above are the company’s statements as carried by multiple outlets. BDX closed at 180.30, within 0.2% of Monday’s close.
Who is replacing Kevin Lobo as Stryker CEO?
Spencer Stiles, Stryker’s President and Chief Operating Officer, becomes CEO on January 1, 2027, and joins the board; Kevin Lobo steps down as CEO and Board Chair on the same date, per the 8-K Stryker filed October 6.
Lobo has led Stryker since 2012, a run that took the company into surgical robotics and made it one of the largest pure play medical technology companies. The release frames the handoff as planned: Lobo said he and the board worked closely on succession and that the company’s foundation made this the right time, and lead independent director Sheri McCoy called Stiles a proven leader. Stiles is a longtime Stryker executive who was elevated to President and COO before this appointment. SYK closed at 278.20 on Tuesday, down 2.5%, giving back part of Monday’s 3.5% gain.
The succession adds to an unusually busy season for medtech leadership: Bavarian Nordic has announced a CEO departure without naming a successor, and Travere’s new chief executive takes over December 1.
What would the NRC’s DG-8070 draft change for radioligand therapy?
Draft regulatory guide DG-8070 would raise the caregiver occupancy assumption used in patient release calculations from 0.25 to 1.0 and evaluate radiation exposure per full treatment course rather than per administration, changes that would push a standard six dose Pluvicto course over the release threshold.
The Nuclear Regulatory Commission issued the draft guide in August 2026, and the industry pushback reached full volume this week, per Fierce Healthcare’s October 6 report. The arithmetic drives the concern: a complete Pluvicto course delivers 44.4 GBq, and under per course accounting that exceeds the 41 GBq threshold for releasing a patient after treatment, meaning clinics would need to hospitalize patients or run individualized, patient by patient physics calculations that smaller community sites are not staffed for. Novartis, Eli Lilly, the Society of Nuclear Medicine and Molecular Imaging, the American Association of Physicists in Medicine, and the American College of Radiology have all objected, and the NRC’s own Advisory Committee on the Medical Uses of Isotopes recommends more realistic assumptions before the guide is finalized.
The commercial stakes run through the outpatient delivery model. Pluvicto generated $493 million in US sales in the second quarter of 2026, up 38% year over year, and more than half of its roughly 900 US treatment sites deliver doses in community settings, per Fierce. The draft landed a day after GE HealthCare agreed to pay $945 million for Sofie Biosciences and its network of radiopharmacy production sites, a deal built on the premise that delivery geography is the scarce asset in radiopharma. DG-8070 is a draft, not a rule, but it is a live reminder that the final mile of nuclear medicine is regulated as well as manufactured.
What did Forbion raise and who backed it?
Forbion closed €2.3 billion ($2.6 billion) across two new funds, Growth Opportunities Fund IV and Ventures Fund VIII, to back roughly 30 companies; limited partners include MN, PGGM, KfW Capital, the Kauffman Foundation, and Eli Lilly.
The Dutch firm announced the close October 6, bringing its assets under management to €7.5 billion. The growth fund targets later stage biopharma companies in Europe and North America, while the ventures fund backs therapeutics focused biotechs. Managing partner Sander Slootweg framed the raise bluntly: the funds give Forbion significant dry powder in a market characterized by a general shortage of capital. Endpoints News called it the firm’s largest fundraise, with Eli Lilly’s participation as a limited partner continuing the pattern of strategics buying early visibility into European deal flow. Against a backdrop where US issuers are paying real discounts for follow on capital and the IPO queue is rebuilding (Lycia Therapeutics filed to go public Monday while TRexBio and Retension set terms, per Endpoints), a dedicated €2.3 billion pool makes Forbion one of the few buyers of first resort for European late stage assets.
Which stocks moved on the day’s news?
ArriVent’s 47.0% collapse was the session’s defining move; Vaxcyte and Spyre repriced on their offerings, and Stryker gave back part of Monday’s gain on the CEO handoff.
| Company | Ticker | October 6 close | Change | Context |
|---|---|---|---|---|
| ArriVent BioPharma | AVBP | 15.09 | −47.0% | FURVENT missed its primary endpoint |
| Spyre Therapeutics | SYRE | 80.11 | −13.6% | First session after Monday’s $85.00 offering price; closed below the offer |
| Vaxcyte | PCVX | 66.70 | −9.6% | Launched roughly $1 billion in offerings; equity priced at $64.00 after the close |
| Stryker | SYK | 278.20 | −2.5% | CEO succession announced; gave back part of Monday’s gain |
| Genmab | GMAB | 37.80 | −1.8% | Day after the session that carried both Rina-S and the Epkinly first line win |
Closes are settled exchange prices; percentage changes are our arithmetic against Monday, October 5 settled closes.
Frequently asked questions
Did firmonertinib show any activity in FURVENT?
Yes. At 240 mg it produced a 60% confirmed response rate versus 33% for chemotherapy and a four month advantage in investigator assessed PFS. The trial still failed because the primary endpoint, PFS by blinded central review, did not reach statistical significance (p=0.0654).
Why did a hazard ratio of 0.75 fail the trial?
A hazard ratio describes the size of the effect; the p value describes the confidence in it. FURVENT’s 0.75 came with a confidence interval of 0.55 to 1.02, which crosses 1.0, and a p value of 0.0654, above the prespecified bar, so chance could not be excluded to the required standard.
What happens to ArriVent now?
The company says it is evaluating the full FURVENT dataset before deciding firmonertinib’s path. It retains FDA Breakthrough Therapy designation in this population, and the active looking 240 mg arm leaves open options in later lines or refined populations, but the first line opportunity priced into the stock is gone for now.
Does the FURVENT failure affect Cullinan’s zipalertinib?
Not directly. Zipalertinib’s second line FDA decision, due February 27, 2027, rests on its own data. Indirectly, the failure removes a future first line competitor but also shows that exon 20 PFS trials against active comparators are hard, which is relevant to Cullinan’s first line rolling submission.
What is the standard first line treatment for EGFR exon 20 insertion NSCLC?
Amivantamab plus platinum based chemotherapy, Johnson & Johnson’s combination, remains the approved first line option in this mutation after FURVENT’s miss.
How much did Vaxcyte raise and on what terms?
Roughly $1 billion before fees: about $500 million of stock at $64.00 per share (7,412,500 shares plus 400,000 pre funded warrants) and $500 million of 1.50% convertible senior notes due 2032 with an initial conversion price near $89.60.
When do Vaxcyte’s offerings close?
Both the equity and the convertible notes are expected to close on October 9, 2026, subject to customary conditions. Underwriters hold 30 day options for up to 1,171,875 additional shares and up to $75 million of additional notes.
Why did Vaxcyte stock fall 9.6% on October 6?
The company announced the proposed offerings that morning, one day after the stock rose 30.7% on its OPUS-1 Phase 3 win. Follow on launches routinely pull a stock toward the expected pricing level; the equity ultimately priced at $64.00, about 4.0% below the day’s settled close.
What did EPCORE DLBCL-2 show?
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed DLBCL, with a hazard ratio of 0.49 (p<0.0001) in the primary IPI 3 to 5 population and the same 0.49 across all enrolled patients.
When could epcoritamab be approved in first line DLBCL?
No timeline exists yet. AbbVie and Genmab say they will engage global regulatory authorities to determine next steps, and the full dataset is being held for presentation at a future medical meeting.
What does BD get from its $19 billion pledge?
Relief from future Section 232 tariffs on applicable products, per the company’s statement. BD itself notes the final rates, timing, and scope are not set, so the value of that relief is not yet quantifiable.
When does Kevin Lobo leave Stryker?
January 1, 2027. Spencer Stiles, currently President and COO, becomes CEO and joins the board on that date, per Stryker’s October 6 filing.
What is NRC draft guide DG-8070?
A draft regulatory guide the Nuclear Regulatory Commission issued in August 2026 governing when patients can be released after receiving radioactive therapies. It proposes a caregiver occupancy assumption of 1.0 (from 0.25) and per course exposure accounting, which professional societies say would force unnecessary hospitalizations.
Would DG-8070 stop Pluvicto treatment?
No. It would make delivery harder in outpatient and community settings, because a full six dose course (44.4 GBq) would exceed the 41 GBq release threshold under the draft’s accounting. The guide is not final, and the NRC’s own advisory committee recommends revisiting its assumptions.
What did Forbion raise?
€2.3 billion ($2.6 billion) across Growth Opportunities Fund IV and Ventures Fund VIII, to invest in roughly 30 companies. Limited partners include MN, PGGM, KfW Capital, the Kauffman Foundation, and Eli Lilly.
Sources
Primary sources: ArriVent BioPharma press release, October 6, 2026 (filed as exhibit 99.1 to Form 8-K, SEC); Vaxcyte pricing press release, October 6, 2026, and preliminary prospectus supplement (Form 424B5, SEC, October 5, 2026); AbbVie and Genmab joint press release, October 5, 2026 (AbbVie newsroom); Stryker Form 8-K and exhibit 99.1, October 6, 2026 (SEC); Forbion press release, October 6, 2026 (GlobeNewswire); US Nuclear Regulatory Commission draft regulatory guide DG-8070, August 2026.
Trade press and market data: Fierce Pharma and Reuters on BD’s investment pledge, October 6, 2026 (BD company statement; primary release not retrieved at publication time); Fierce Healthcare on DG-8070 and Pluvicto, October 6, 2026 (Pluvicto Q2 sales and site figures attributed to this report); Fierce Biotech, October 6, 2026 (AstraZeneca Kendall Square); Endpoints News, October 5, 2026 (IPO queue); MedTech Dive and Manufacturing Dive, October 6, 2026 (BD agreement). Settled closing prices from exchange data, October 6, 2026; percentage changes are our arithmetic.
Related coverage
- Vaxcyte’s VAX-31 met all primary endpoints in its pivotal adult Phase 3 as Shionogi paid $2 billion for IntraBio and GE HealthCare bought Sofie for $945 million
- Novartis paid $575 million upfront for Abogen’s mRNA T cell engager as CSL bet $355 million on Alentis and Genmab’s Rina-S hit 45.9% in ovarian cancer
- Regeneron’s trevogrumab preserved muscle lost on semaglutide at 52 weeks as survodutide cut weight 13.1% in Phase 3 and Sanofi paid $1 billion for four Dupixent successors
